Gefitinib

Rezivertinib demonstrated significantly longer progression-free survival (19.3 months vs 9.6 months) compared to gefitinib in patients with EGFR-mutated non-small cell lung cancer in the Phase III REZOR trial.

• Ignota Labs has raised $6.9 million in seed funding to expand its pipeline of distressed drug assets and advance its first PDE9A inhibitor into early clinical trials. • The company's SAFEPATH platform combines AI, cheminformatics, and bioinformatics to identify and resolve drug toxicity issues, addressing a problem that causes 56% of clinical trial failures. • Ignota Labs has already demonstrated success by in-licensing a first-in-class metabolic health drug for post-menopausal women and resolving its safety concerns through their platform.

Ocean Biomedical's breakthrough research demonstrates their immunotherapy candidates can synergize with tyrosine kinase inhibitors like osimertinib to suppress tumor growth in EGFR-mutant lung cancer.

Targeted therapies for NSCLC have revolutionized treatment for patients with specific genetic alterations, with EGFR, ALK, and ROS1 inhibitors showing significant improvements in progression-free survival compared to traditional chemotherapy.

Gastrointestinal organoids have emerged as powerful three-dimensional models that bridge the gap between traditional cell cultures and animal models, offering superior disease modeling capabilities for colorectal cancer research.